Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the α-isoform of the folate receptor

Cancer Research

Volumn 63, Issue 13, 2003, Pages 3612-3618

  Theti, Davinder S ^a   Bavetsias, Vassilios ^a   Skelton, Lorraine A ^a   Titley, Jenny ^a   Gibbs, David ^a   Jansen, Gerrit ^b   Jackman, Ann L ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CB 300638; FOLATE RECEPTOR ALPHA; FOLIC ACID; FOLINIC ACID; MEMBRANE RECEPTOR; METHOTREXATE; QUINAZOLINE DERIVATIVE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN KB; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENDOSOME; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MEMBRANE TRANSPORT; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL DIVISION; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; FOLIC ACID; HUMANS; KINETICS; QUINAZOLINES; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; THYMIDYLATE SYNTHASE; TRANSFECTION; TUMOR CELLS, CULTURED; VULVAR NEOPLASMS;

EID: 0037742256     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Jansen, G. Receptor- and carrier-mediated transport systems for folates and antifolates. In: A. L. Jackman (ed.), Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy pp. 293-321. Totowa, NJ: Humana Press Inc., 1999.
2. Antony, A. C. Folate receptors. Ann. Rev. Nutr., 16: 501-521, 1996.
3. Kamen, B. A. Folate receptor α: an update. In: E. J. Massaro and J. M. Rogers (eds.), Folate and Human Development. Totowa, NJ: Humana Press Inc., 117-136, 2002.
4. Rijnboutt, S., Jansen, G., Posthuma, G., Hynes, J. B., Schornagel, J. H., and Strous, G. J. A. M. Endocytosis of GPI-linked membrane folate receptor-α. J. Cell Biol., 132: 35-47, 1996.
5. Hjelle, J. T., Christensen, E. I., Carone, F. A., and Selhub, J. Cell fractionation and electron microscope studies of kidney folate-binding protein. Am. J. Physiol., 260: 338-346, 1991.
6. Anderson, R. G. W., Kamen, B. A., Rothberg, K. G., and Lacey, S. W. Potocytosis; sequestration and transport of small molecules by caveolae. Science (Wash. DC), 225: 410-411, 1992.
7. Ross, J. F., Chaudhuri, P. K., and Ratnam, M., Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer (Phila.), 73: 2432-2443, 1994.
8. Weitman, S. D., Lark, R. H., Coney, L. R., Fort, D. W., Frasca, V., Zurawski, V. R., and Kamen, B. A. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res., 52: 3396-3401, 1992.
9. Holm, J., Hansen, S. I., Hoier-Madsen, M., and Bostad, L. High affinity folate-binding in human choroid plexus. Characterisation of radioligand binding, immuno-reactivity, molecular heterogeneity and hydrophobic domain of the binding protein. Biochem. J., 280: 267-271, 1991.
10. Morshed, K. M., Ross, D. M., and McMartin, K. E. Folate transport proteins mediate the bi-directional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J. Nutr., 127: 1137-1147, 1997.
11. Reddy, J. A., and Low, P. S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Systems, 15: 587-627, 1998.
12. Bueno, R., Appasani, K., Mercer, H., Lester, S., and Sugarbaker, D. The a folate receptor is highly activated in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg., 121: 225-233, 2001.
13. Wu, M., Gunning, W., and Ratnam, M. Expression of folate receptor type a in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol. Biomark. Prev., 8: 775-782, 1999.
14. Garin-Chesa, P., Campbell, I., Saigo, P. E., Lewis, J. L., Old, L. J., and Rittig, W. J. Trophoblast and ovarian cancer antigen LK26: sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol., 142: 557-567, 1993.
15. Campbell, I. G., Jones, T. A., Foulkes, W. D., and Trowsdale, J. Folate-binding protein is a marker for ovarian cancer. Cancer Res., 51: 5329-5338, 1991.
16. Toffoli, G., Cernigoi, C., Russo, A., Gallo, A., Bagnoli, M., Boicchi, M. Overexpression of folate binding protein in ovarian cancers. Int. J. Cancer, 74: 193-198, 1997.
17. Toffoli, G., Russo, A., Gallo, A., Cernigio, C., Miotti, S., Sorio, R., Tumolo, S., Boiocchi, M. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int. J. Cancer, 79: 121-126, 1998.
18. Shen, F., Zheng, X., Wang, J., and Ratnam, M. Identification of amino acid residues that determine the differential ligand specificities of folate receptors α and β. Biochemistry, 36: 6157-6163, 1997.
19. Wang, X., Shen, F., Freisheim, J. H., Gentry, L. E., and Ratnam M. Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol., 44: 1898-1901, 1992.
20. Gates, S. B., Mendelsohn, L. G., Shackelford, K. A., Habeck, L. L., Kursar, J. D., Gossett, L. S., Worzalla, J. F., Shih, C., and Grindey, G. B. Characterization of folate receptor from normal and neoplastic tissue: influence of dietary folate on folate receptor expression. Clin. Cancer Res., 2: 1135-1141, 1996.
21. + cells. Blood, 93: 3940-3948, 1999.
22. Shen, F., Ross, J. F., Wang, X., and Tatnam, M. Identification of a novel folate receptor, a truncated receptor, and receptor type β in hematopoeitic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry, 33: 1209-1215, 1994.
23. Shen, F., Wu, M., Ross, J. F., Miller, D., and Ratnam, M. Folate receptor type γ is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterisation and cell type specificity. Biochemistry, 34: 5660-5665, 1995.
24. Miotti, S., Bagnoli, M., Tomassetti, A., Colnaghi, M. I., and Canevari, S. Interaction of folate receptor with signalling molecules lyn and Gai-3 in detergent-resistant complexes from the ovary carcinoma cell line IGROV1. J. Cell Sci., 113: 349-357, 2000.
25. Gruner, B. A., and Weitman, S. D. The folate receptor as a potential therapeutic anticancer target. Investig. New Drugs, 16: 205-219, 1998.
26. Leamon, C. P., and Low, P. S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discovery Today, 6: 44-51, 2001.
27. Mathius, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., and Greem, M. A. Indium-111-DPTA-folate as a potential folate-receptor-targeted radiopharmaeutical. J. Nucl. Med., 39: 1579-1585, 1998.
28. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
29. Jackman, A. L., Boyle, F. T., and Harrap, K. R. Tomudex (ZD1694): From concept to care, a programme in rational drug discovery. Investig. New Drugs, 14: 305-316, 1996.
30. Jackman, A. L., Kimbell, R., Aherne, G. W., Brunton, L., Jansen, G., Stephens, T. C., Smith, M., Wardleworth, J. M., and Boyle, F. T. The cellular pharmacology and in vivo activity of a new anticancer agent. ZD9331: a water-soluble, non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res., 3: 911-921, 1997.
31. Shih, C., Chen, V. V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., Andis, S. L., Bewley, J. R., Rayl, E. A., Morrison, B. A., Beardsley, G. P., Kohler, W., Ratnam, M., and Schultz, R. M. LY231514, a pyrrolo[2, 3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes. Cancer Res., 57: 1116-1123, 1997.
32. Mendelsohn, L. G., Worzalla, J. F., and Walling, J. M., Preclinical and clinical evaluation of the glycinamide ribonucleotide formyltransferase inhibitors Lometrexol and LY309887. In: A. L. Jackman (ed.), Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, pp. 261-280. Totowa, NJ: Humana Press Inc., 1999.
33. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier and receptor-mediated transport of folate antagonists targeting folate dependent enzymes: correlates of molecular-structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
34. Shih, C., and Thornton, D. E. Preclinical pharmacological studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: A. L. Jackman (ed.), Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, pp. 183-201. Totowa, NJ: Humana Press Inc., 1999.
35. Jackman, A. L., and Calvert, A. H., Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
36. 10-propargyl-5, 8-dideazafolic acid and related compounds in murine (L1210) and human (WIL2) systems in vitro and in vivo. Cancer Res., 50: 5212-5218, 1990.
37. Westerhof, G. R., Jansen, G., Van Emmerik, N., Kathmann, I., Rijksen, G., Jackman, A. L., and Schornagel, J. H. Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: The role of carrier- and receptor-mediated transport systems. Cancer Res., 51: 5507-5513, 1991.
38. Jansen, G., Schornagel, J. H., Westerhof, G. R., Rijksen, G., Newell, D. R., and Jackman, A. L. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res., 50: 7544-7548, 1990.
39. Bavetsias, V., Marriott, J. H., Melin, C., Kimbell, R., Matusiak, Z., Boyle, F. T., and Jackman, A. L. Synthesis of cyclopenta[g]quinazoline-based antifolates, a novel class of thymidylate synthase inhibitors. J. Med. Chem., 43: 1910-1926, 2000.
40. Melin, C., Kimbell, R., Brunton, L., Bavetsias, V., Marriott, J. H., and Jackman, A. L. Novel cyclopenta[g]quinazoline dipeptide antifolates: thymidylate synthase inhibitors with activity independent of the reduced-folate carrier and folylpolyglutamate synthetase In: W. Pfleiderer and H. Rokos (eds.), Chemistry and Biology of Pteridines and Folates. 1997. pp. 139-144. Berlin: Blackwell Wissenschafts-Verlag, 1997.
41. Theti, D. S. Development of a novel class of thymidylate synthase inhibitor targeted to α-folate receptor overexpressing tumours. Ph. D thesis. London: University of London, Unitéd Kingdom.
42. Bavetsias, V., Marriott, J. H., Theti, D., Melin, J. C., Wilson, S. C., and Jackman, A. L. Cyclopenta[g]quinazoline-based antifolates: the effect of the chirality at the 6-position on the inhibition of thymidylate synthase. Bioorg. Med. Chem. Lett., 11: 3015-3017, 2001.
43. Jansen, G., Westerhof, G. R., Kathmann, I., Rademaker, B. C., Rijksen, G., and Schornagel, J. H. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport related methotrexate resistance. Cancer Res., 49: 2455-2459, 1989. (correction in Cancer Res., 55: 4203. 1995; cell line now designated L1210-FBP).
44. Jansen, G., Westerhof, G. R., Kathmann, I., Rademaker, B. C., Rijksen, G., and Schornagel, J. H. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport related methotrexate resistance. Cancer Res., 49: 2455-2459, 1989. (correction in Cancer Res., 55: 4203. 1995; cell line now designated L1210-FBP).
45. Jones, T. R., Calvert, A. H., Jackman, A. L., Brown, S. J., Jones, M., and Harrap, K. R. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur. J. Cancer, 17: 11-19, 1981.
46. Henderson, P. J. F. Steady-state enzyme kinetics with high-affinity substrates or inhibitors. Biochem. J., 280: 101-107, 1973.
47. Bagnoli, M., Tomassetti, A., Figini, M., Flati, S., Dolo, V., Canevari, S., and Miotti, S. Down modulation of caveolin-1 expression in human ovarian carcinoma is directly related to α-folate receptor overexpression. Oncogene, 19: 4754-4763, 2000.
48. Miotti, S., Canevari, S., Menard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterisation of human ovarian-associated antigens defined by novel antibodies with tumour-restricted specificity. Int. J. Cancer, 39: 297-303, 1987.
49. Skelton, L. A., Ormerod, M. G., Titley, J., Kimbell, R., Brunton, L. A., and Jackman, A. L. A novel class of lipophilic quinazoline-based folic acid analgues: cytotoxic agents with a folate-independent locus. Br. J. Cancer, 79: 1692-1701, 1999.
50. Twentyman, P. R., and Luscombe, M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br. J. Cancer, 56: 279-285, 1987.
51. Taylor, G. A., Jackman, A. L., Balmanno, K., Hughes, L. R., and Calvert, A. H. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells. In: K. Mikgnayi, K. Nifhioke, and W. N. Kelly (eds.), Purine Metabolism in Man VI. Part B: Basic Research and Experimental Biology, pp. 383-388. New York and London: Plenum Press, 1989.
52. Peters, G. J., and Kohne, C. H. Fluoropyrimidines as antifolate drugs. In: A. L. Jackman (ed.). Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, pp. 293-321. Totowa, NJ: Humana Press Inc., 1999.
53. Jackman, A. L., Taylor, G. A., Calvert, A. H., and Harrap, K. R. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor. CB 3717. Biochem. Pharmacol., 33: 3269-3275, 1984.
54. Theti, D. S., Bavetsias, V., Gibbs, D. D., Skelton, L. A., and Jackman, A. L. rate of thymidylate synthase inhibition by CB300638 in the human A431-FBP cell line transfected with the α-isoform of the folate receptor. Proc. Am. Assoc. Cancer Res., 42: 291, 2001.